Background: Recurrent miscarriage (RM) impacts 1%-2% of fertile couples and is characterized by 3 or more consecutive miscarriages during the 1st trimester of gestation. It's a prevalent reproductive burden on public health, producing both emotional and physical anguish. There is no therapy that has been proven to be beneficial to date. Aim of the work:To determine whether hydroxychloroquine (given orally prior to conception and for the first ten weeks of pregnancy) could increase the live birth rate by 15% or more in women with a prior RM. Patients and methods: We conducted a double-blind, randomized, placebo-controlled study on 300 female participants suffering from recurrent miscarriages. At randomization, the minimization approach will be utilized to balance the two groups and two major predictors of miscarriage recurrence: mother age (≤35 or >35 years) and the number of prior miscarriages (3 or ≥4). Results: The current study showed that 30% of study female patients completed their pregnancy after taking hydroxychloroquine (HCQ), while 70% of them did not complete the pregnancy. The difference in mean age between cases and controls was statistically significant (P = 0.001). Conclusion:We obtained some significant positive results regarding the orally administrated HCQ usage to increase the live birth rate in women suffering from recurrent miscarriages.